Resumo

SOUSA, H. T. et al. Eficácia e segurança do infliximab no tratamento da doença de crohn: experiência de um centro português. J Port Gastrenterol. [online]. 2006, vol.13, n.2, pp.75-81. ISSN 0872-8178.

Aims: Evaluation of efficacy and safety of infliximab treatment in Crohn's disease (CD), performed at our department. Methods: Medical records of patients with CD followed at our department and treated with infliximab until 2004 were reviewed. Results: Fifty-four (18,7%) patients with CD were treated with infliximab. Fifty-two patients were studied, with a 8,5 (1-28) year DC on average. Indications for treatment were inflammatory luminal disease in 24 (46,2%) patients, active fistulas in 22 (42,3%) and both in 6 (11,5%). Each patient received 4,3 (1-24) infusions, on average, for a total of 226 infusions. On starting infliximab, 84,6% of patients were also on imunossupressive treatment. Adverse events occurred in 19 (36,5%), being serious in 9 (17,3%). In about 2/3 of patients responded to the induction scheme and 3/4 of patients on maintenance uphold a positive response. At the end of follow-up, 28 (53,0%) patients sustained a positive response, with 13 (25,0%) in complete remission. Conclusions: Half of the patients clinically and steadily improved, with half of these in complete remission. Adverse events occurred in about 1/3 of patients, which warranted discontinuation of treatment in less than 10%.

        · resumo em Português     · texto em Português     · Português ( pdf )